Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
18.01
-0.58 (-3.12%)
At close: Apr 28, 2026, 4:00 PM EDT
17.65
-0.36 (-2.00%)
After-hours: Apr 28, 2026, 7:07 PM EDT
Zenas BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 10 | 5 | 50 | - |
| Revenue Growth (YoY) | 100.00% | -90.00% | - | - |
| Cost of Revenue | - | - | 60.03 | 61.69 |
| Gross Profit | 10 | 5 | -10.03 | -61.69 |
| Selling, General & Admin | 53.32 | 29.75 | 17.11 | 13.51 |
| Research & Development | 168.06 | 139.14 | - | - |
| Operating Expenses | 221.39 | 168.89 | 17.11 | 13.51 |
| Operating Income | -211.39 | -163.89 | -27.15 | -75.2 |
| Interest Expense | -7.33 | - | - | - |
| Interest & Investment Income | 12.15 | 7.97 | - | - |
| Currency Exchange Gain (Loss) | 0.3 | - | 0.1 | - |
| Other Non Operating Income (Expenses) | 0.12 | 0.2 | 0.52 | -43.08 |
| EBT Excluding Unusual Items | -206.14 | -155.71 | -26.52 | -118.28 |
| Other Unusual Items | - | -0.85 | -0.3 | - |
| Pretax Income | -377.82 | -156.56 | -36.82 | -119.28 |
| Income Tax Expense | -0.08 | 0.43 | 0.3 | - |
| Net Income | -377.74 | -156.99 | -37.12 | -119.28 |
| Net Income to Common | -377.74 | -156.99 | -37.12 | -119.28 |
| Shares Outstanding (Basic) | 45 | 13 | 2 | 1 |
| Shares Outstanding (Diluted) | 45 | 13 | 2 | 1 |
| Shares Change (YoY) | 238.89% | 762.01% | 2.61% | - |
| EPS (Basic) | -8.44 | -11.89 | -24.25 | -79.94 |
| EPS (Diluted) | -8.44 | -11.89 | -24.25 | -79.94 |
| Free Cash Flow | -172.35 | -119.81 | -30.55 | -65.85 |
| Free Cash Flow Per Share | -3.85 | -9.08 | -19.95 | -44.13 |
| Gross Margin | 100.00% | 100.00% | -20.07% | - |
| Operating Margin | -2113.85% | -3277.76% | -54.29% | - |
| Profit Margin | -3777.37% | -3139.76% | -74.25% | - |
| Free Cash Flow Margin | -1723.51% | -2396.10% | -61.09% | - |
| EBITDA | -211.33 | -163.75 | -27.03 | -75.12 |
| EBITDA Margin | - | - | -54.07% | - |
| D&A For EBITDA | 0.06 | 0.14 | 0.11 | 0.08 |
| EBIT | -211.39 | -163.89 | -27.15 | -75.2 |
| EBIT Margin | - | - | -54.29% | - |
| Revenue as Reported | 10 | 5 | 50 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.